Biomarkers for EGFR-antagonist response: in the genes and on the genes!
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22371454.
- Also identified by DOI 10.1158/1078-0432.CCR-12-0157 and PMC identifier 3586523.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with non-small cell lung carcinoma containing epidermal growth factor receptor (EGFR)-activating mutations benefit from EGFR-antagonist therapy. EGFR-antagonist sensitivity is also correlated with epithelial-mesenchymal transition, which Walter and colleagues show to be marked by DNA-methylation changes. If validated, these markers could help identify patients with wild-type EGFR who will benefit from EGFR therapy.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- DNA Methylation
- Lung Neoplasms